Lionel Bonaventure/AFP/Getty Images

Antitrust charges against Israel-based Teva were filed by European regulators because the drugmaker allegedly colluded to delay a cheaper generic version of its sleep drug modafinil. The regulators allege that Teva agreed with rival Cephalon not to sell a cheaper modafinil generic in exchange for "a substantial transfer of value from Cephalon through a series of cash payments and various other agreements."

Related Summaries